News | March 04, 2021
COVAXIN demonstrates interim clinical efficacy of 81%
Bharat Biotech expects to share further details of the trial results as additional data become available.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The jump in profit is due to the better performance of the API business.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
